Abstract
The development of artificial blood had been proceeded through the development research of the artificial oxygen carrier to substitute for the blood transfusion. We have developed the liposome encapsulated hemoglobin that have superior function for oxygen transport which was close to red blood cell as the biomimetics-technology of red blood cell. The function of oxygen transport was designed that the P 50 value was controlled to 40-50 torr to use the inositol-hexaphosphate as an allosteric effector. The oxygen transporting efficiency of NRC under respiration with 30-50% oxygen was superior to that of human red blood cells (hRBC). NRC showed double efficacy per g-Hb in comparison with hRBC. To mimic the methemoglobin reduction system of red blood cell, the stroma-free hemoglobin (SFH) was prepared with preserving the methemoglobin (metHb) reducing enzymatic activities of red blood cell. We have succeeded that methemoglobin reduction system of red blood cells was mimicked within liposomes.
The development of the artificial oxygen carrier will be able to evolve to aim at the treatment for the stroke and the myocardial infarction as oxygen infusion liquid from the blood substitution in future. So, development of the function design will change from the blood substitution to the therapeutic purposes.
